Cell & Gene Therapy 2021
bit.bio
Where: 01
bit.bio is an award-winning human synthetic biology enterprise. bit.bio's mission is to code cells for novel cures. Our vision is biomedical innovation and a new generation of cures through precision engineered human cells.

bit.bio was founded out of CEO Mark Kotter’s laboratories at Cambridge University in 2016. Based on a unique approach to biology and the foundational capabilities to precisely reprogram human cells, bit.bio is poised to become a cornerstone in the upcoming regenerative medicine revolution. With just one cell type we are seeing a revolution in cancer care.

bit.bio is working to generalise this precision cellular reprogramming approach across the whole human cell type spectrum. The possibilities for research, drug discovery and novel cures for patients are endless. With a revolutionary range of definitive, coded cells - precision-engineered human iPSC-derived cells driven with our unique opti-ox™ technology that offer speed, reliability and consistency at scale for research and drug discovery.

"At bit.bio, we are passionate about engineering human cells that will enable the medicine of the future." Mark Kotter | MD, PhD, Founder | CEO
Tel: 01223 787 297
Address: The Dorothy Hodgkin Building
Babraham Research Campus
Cambridge
Website: https://bit.bio/
Email: info@bit.bio

Staff Attending

Ms Abbey Crawford
Commercial Marketing Manager
Bit Bio Limited
Dr Alex Davenport
bit.bio
Kam Dhaliwal
SVP Alliance Management
bit.bio
Dr Tonya Frolov
Product Manager
bit.bio
Miss Roisin Nicoll
Sales Manager
Bit Bio
Dr Farah Patell-Socha
VP Research Products
bit.bio Ltd

Find out more...

To view the virtial stand - please login first Brochure ioGlutamatergic Neurons – Human induced neurons for research and HTS – Flyer

Brochure ioGlutamatergic Neurons – Poster by Charles River, validating the neurons for HTS

Brochure ioGlutamatergic Neurons – Additional resources

Brochure ioSkeletal Myocytes – Human induced skeletal muscle cells for research and HTS – Poster by bit.bio

Brochure ioSkeletal Myocytes – Additional resources

Brochure Original paper describing opti-ox reprogramming – Pawlowski et al., Stem Cell Reports, 2017

Brochure 'Reprogramming the stem cell for a new generation of cures' – Drug Discovery World, Spring 2020

Brochure Charles River Announces Strategic Partnership with bit.bio

Brochure bit.bio Secures Distribution Agreement with Abcam

Brochure bit.bio secures $41.5 million of funding from top life sciences investors

Brochure ioGlutamatergic Neurons – Human induced neurons for research and HTS – Flyer

Brochure ioGlutamatergic Neurons – Poster by Charles River, validating the neurons for HTS

Brochure ioGlutamatergic Neurons – Additional resources

Brochure ioSkeletal Myocytes – Human induced skeletal muscle cells for research and HTS – Poster by bit.bio

Brochure ioSkeletal Myocytes – Additional resources

Brochure Original paper describing opti-ox reprogramming – Pawlowski et al., Stem Cell Reports, 2017

Brochure 'Reprogramming the stem cell for a new generation of cures' – Drug Discovery World, Spring 2020

Brochure Charles River Announces Strategic Partnership with bit.bio

Brochure bit.bio Secures Distribution Agreement with Abcam

Brochure bit.bio secures $41.5 million of funding from top life sciences investors

LinkedIn URL

Twitter